Eyenovia to Report Third Quarter 2023 Results on Monday, November 13

Rhea-AI Summary

Eyenovia, Inc. (NASDAQ: EYEN) will release its financial results for the third quarter ended September 30, 2023, on November 13, 2023. The company will host an investor conference call and webcast at 4:30 p.m. EDT to review the financial and operating results. Eyenovia is an ophthalmic technology company commercializing Mydcombi™ for mydriasis and preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery. They are also incorporating their advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications.

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the Company will release financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13741898.

To access the Call me™ feature, which avoids having to wait for an operator, click here.

A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis.

In addition to commercializing Mydcombi, in August 2023, Eyenovia acquired the U.S. commercial rights to APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) from Formosa Pharmaceuticals. APP13007, which is currently under review by the FDA, is a potent steroid being developed to reduce pain and inflammation following ocular surgery. The agency has assigned a Prescription Drug User Fee Act (PDUFA) action date for APP13007 of March 4, 2024.

Eyenovia is also advancing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb in the U.S. and Canada and Arctic Vision in China and South Korea).

For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

FAQ

When will Eyenovia release its financial results for Q3 2023?

Eyenovia will release its financial results for the third quarter ended September 30, 2023, on November 13, 2023.

What is Eyenovia's stock ticker symbol?

Eyenovia's stock ticker symbol is EYEN.

What is Mydcombi™ and what is it used for?

Mydcombi™ is a product commercialized by Eyenovia for mydriasis, which is the dilation of the pupil.

What is APP13007 and what is it used for?

APP13007 is a product being prepared by Eyenovia for regulatory approval. It is used for relief of pain and inflammation post ocular surgery.

What is Optejet® and how is it being incorporated?

Optejet® is an advanced device developed by Eyenovia. It is being incorporated with late-stage product candidates for presbyopia and pediatric progressive myopia, as well as for out-licensing for additional indications.

Where can I access the live webcast of Eyenovia's conference call?

The live webcast of Eyenovia's conference call will be available on the investor relations page of the company's corporate website at www.eyenovia.com.

How long will the archived event be available on Eyenovia's website?

The archived event will be available on Eyenovia's website for one year.